Therapeutic options for resistant cytomegalovirus retinitis

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 14, Issue SUPPL. 1, 1997, Pages

  Kuppermann, Baruch D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Cidofovir; CMV resistance; CMV retinitis; Cytomegalovirus; Fomivirsen; Foscarnet; Ganciclovir; Ganciclovir implant; HIV; HPMPC; Intraocular cidofovir; Intravitreal foscarnet; Intravitreal ganciclovir; ISIS 2922; PCR

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROBENECID; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL MODEL; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; EYE TOXICITY; FATIGUE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAOCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; INTRAVITREAL DRUG ADMINISTRATION; IRITIS; MALAISE; MOUSE; MULTICENTER STUDY; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RETINITIS; TREATMENT OUTCOME;

ANIMALIA; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030941449     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199700001-00004     Document Type: Conference Paper

References (40)

1. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE, and the Zidovudine Epidemiology Study Group. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992;166:1223-7.
2. Freeman WR, Lerner CW, Mines, JA, et al. A prospective study of the ophthalmologic findings in the acquired immune deficiency syndrome. Am J Ophthalmol 1984;97:133-42.
3. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989;107:75-80.
4. Polis MA, Masur H. Promising new treatments for cytomegalovirus retinitis. JAMA 1995;273:1457-9.
5. Holland GN, Pepose JS, Pettit TH, Gottlieb MS, Yee RD, Foos RY. Acquired immune deficiency syndrome: ocular manifestations. Ophthalmology 1983;90:859-73.
6. Spector SA, Weingeist T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. J Infect Dis 1993;168:557-63.
7. Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991; 115:665-73.
8. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-20.
9. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Foscarnet-ganciclovir cytomegalovirus retinitis trial: 4. Visual outcomes. Ophthalmology 1994;101:1250-61.
10. Chou S, Guentzel S, Michels KR, Miner RC, Drew WL. Frequency of UL 97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995;172:239-42.
11. Kuppermann BD, Flores-Aguilar M, Quiceno JI, Rickman LS, Freeman WR. Combination ganciclovir and foscarnet in the treatment of clinically resistant cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Arch Ophthalmol 1993;111:1359-66.
12. Kuppermann BD, Quiceno JI, Flores-Aguilar M, et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis 1993;168:1506-9.
13. Arevalo JF, Gonzalez C, Capparelli EV, et al. Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. J Infect Dis 1995;172:951-6.
14. Plotkin SA, Drew WL, Felsenstein D, Hirsch MS. Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl) guanine. J Infect Dis 1985;152: 833-4.
15. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991;163:716-9.
16. Drew WL. Cytomegalovirus infection in patients with AIDS. Clin Infect Dis 1992;14:608-15.
17. Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant: a randomized controlled clinical trial. Arch Ophthalmol 1994;112:1531-9.
18. Grossberg HS, Bonnem EM. GM-CSF with ganciclovir for the treatment of CMV retinitis in AIDS. N Engl J Med 1989; 320:1560.
19. Hardy WD. Combined ganciclovir and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. J Acquir Immune Defic Syndr 1991;4(suppl I):S22-8.
20. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Arch Intern Med 1995;155:65-74.
21. Lalezari JP, Kemper C, Stagg R, et al. A randomized, controlled study of the safety and efficacy of intravenous cidofovir (CDV, HPMPC) for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS [Abstract]. Abstracts of the XI International Conference on AIDS 1996; 226:Th.B.304.
22. Lalezari JP, Stagg RJ, Kuppermann BD, et al. A randomized, controlled trial of intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1997 (in press).
23. Stanat SC, Reardon JE, Erice A, Jordan MC, Drew WL, Biron KK. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob Agents Chemother 1991;35:2191-7.
24. Lurain NS, Thompson KD, Holmes EW, Read GS. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents.
25. Freitas VR, Fraser-Smith EB, Matthew TR. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and Herpes simplex virus type 2 in vitro and in vivo. Antiviral Res 1989;12:205-12.
26. Manischewitz JF, Quinnan GV Jr, Lane HC, Wittek AE. Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1990;34:373-5.
27. Cherrington JM, Mulato AS, Fuller M, Chen MS. In vitro selection of a human cytomegalovirus (HCMV) that is resistant to cidofovir [Abstract]. Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995:H117.
28. Cherrington JM, Smith IL, Jiles RE, et al. Ganciclovir resistant CMV: implications of UL97 and polymerase mutations in cross resistance tocidofovir [Abstract]. Antiviral Res 1996;30:A44.
29. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch Ophthalmol 1996;114:23-33.
30. Young SH, Morlet N, Heery S, Hollows FC, Coroneo MT. High dose intravitreal ganciclovir in the treatment of cytomegalovirus retinitis. Med J Aust 1992;157:370-3.
31. Saran BR, Maguire AM. Retinal toxicity of high dose intravitreal ganciclovir. Retina 1994;14:248-52.
32. Diaz-Llopis M, España E, Muñoz G, et al. High dose intravitreal foscarnet in the treatment of cytomegalovirus retinitis in AIDS. Br J Ophthalmol 1994;78:120-4.
33. The Chiron Ganciclovir Implant Study Group. A randomized controlled multicenter clinical trial of a sustained-release intraocular ganciclovir implant in AIDS patients with CMV retinitis [Abstract]. Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy 1995;243:I215.
34. Freeman WR, Friedberg DN, Berry C, et al. Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis. Am J Ophthalmol 1993;116:713-20.
35. Jabs DA, Enger C, Haller J, de Bustros S. Retinal detachments in patients with cytomegalovirus retinitis. Arch Ophthalmol 1991;109:794-9.
36. Kirsch LS, Arevalo JF, Chavez de la Paz E, Manguia D, de Clercq E, Freeman WR. Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1995; 102:533-43.
37. Kirsch LS, Arevalo JF, De Clercq E, et al. Phase I/II study of intravitreal cidofovir for the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol 1995;119:466-76.
38. Rahhal FM, Arevalo F, Munguia D, et al. Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis. Ophthalmology 1996;103:1078-83.
39. Kuppermann B, Wolitz R, Stagg R, et al. A phase II randomized, double-masked study of (IO) intraocular cidofovir for relapsing cytomegalovirus retinitis (CMV-R) in patients with AIDS [Abstract]. Presented at the 14th Annual Meeting of the Vitreous Society, Cancun, Mexico, Dec. 1996.
40. Palestine AG, Cantrill HL, Luckie AP, Ai E. Intravitreal treatment of CMV retinitis with an antisense oligonucleotide, ISIS 2922 [Abstract]. Abstracts of the Xth International Conference on AIDS 1994:332B.